African Head and Neck Society Clinical Practice guidelines for thyroid nodules and cancer in developing countries and limited resource settings

Mark Zafereo MD1  |  Justin Yu BS1  |  Paul A. Onakoya MBBS2  |
Joyce Aswani MMed3  |  Kenneth Baidoo DLO4  |  Mesele Bogale MD5  |
Lydia Cairncross MMed6  |  Susan Cordes MD7  |  Adekunle Daniel MBBS2  |
Evelyne Diom PhD8  |  Mpessa E. Maurice MBBS9  |
Garba M. Mohammed MBBS10  |  Melesse G. Biadgelay MD11  |
Fatogoma I. Koné MBBS12  |  Arnaud Itiere MBBS13  |  Wayne Koch MD14  |
Anna Konney MD15  |  Innocent Kondiona MMed16  |  Chege Macharia MBChB17  |
Victor Mashamba MMed18  |  Michael G. Moore MD19  |
Rajab M. Mugabo MMed20  |  Patrick Noah MBBS21  |  Mary Omutsani MBChB22  |
Lisa A. Orloff MD23  |  Jeffrey Otiti MMed24  |  Gregory W. Randolph MD25  |
Merry Sebelik MD26  |  Tobias Todsen MD PhD27  |  Khaled Twier MD28  |
Johannes J. Fagan MMed28

1Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas
2Department of Otorhinolaryngology, University of Ibadan, Ibadan, Nigeria
3Department of Surgery, College of Health Sciences, University of Nairobi, Nairobi, Kenya
4Department of Otolaryngology, Korle Bu Teaching Hospital, Accra, Ghana
5Department of Surgery, Adama Hospital Medical College, Adama, Ethiopia
6Department of Surgery, Groote Schuur Hospital, Cape Town, South Africa
7Adventist Health, Ukiah, California
8Department of Otolaryngology, Assane Seck University, Ziguinchor, Senegal
9Department of Otolaryngology, University Hospital of Yopougon, Abidjan, Ivory Coast
10Department of Otolaryngology, Kaduna State University, Kaduna, Nigeria
11Department of Surgery, Bahir Dar University, Bahir Dar, Ethiopia
12Department of Head and Neck Surgery, Gabriel Touré University Hospital, Bamako, Mali
13Department of Otorhinolaryngology, General Hospital of Brazzaville, Brazzaville, Congo
14Department of ORL/Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland
15Department of Otolaryngology, Komfo Anokye Teaching Hospital, Kumasi, Ghana
16Department of Otolaryngology, Parirenyatwa Group of Hospitals, Harare, Zimbabwe
17Department of General Surgery, AIC Kijabe Hospital, Kenya
18Department of Otorhinolaryngology, Muhimbili National Hospital, Dar es Salaam, Tanzania
19Department of Otolaryngology-Head and Neck Surgery, Indiana University, Indianapolis, Indiana
20Department of Otolaryngology, King Faisal Hospital, Kigali, Rwanda
21Department of Otolaryngology, India Head and Neck Surgery, Indian Institute, Delhi, India
22Department of Otolaryngology, University of Ibadan, Ibadan, Nigeria
23Department of Otolaryngology, University of Ibadan, Ibadan, Nigeria
24Department of Otolaryngology, University of Ibadan, Ibadan, Nigeria
25Department of Otolaryngology, University of Ibadan, Ibadan, Nigeria
26Department of Otolaryngology, University of Ibadan, Ibadan, Nigeria
27Department of Otolaryngology, University of Ibadan, Ibadan, Nigeria
28Department of Otolaryngology, University of Ibadan, Ibadan, Nigeria
29Department of Otolaryngology, University of Ibadan, Ibadan, Nigeria

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Head & Neck published by Wiley Periodicals, Inc.
1 INTRODUCTION

Thyroid nodules are common and are estimated to occur in at least 33% of the population. Studies suggest that approximately 95% of thyroid nodules are benign and will not progress to malignant disease. However, the rate of malignancy within thyroid nodules may be higher in low resource settings, specifically since nodules are more frequently detected when clinically apparent rather than incidentally. Moreover, approximately 90% of malignant thyroid cancers are well-differentiated histological variants, with the majority diagnosed as papillary (PTC), follicular (FTC), or Hürthle cell thyroid cancers (HTC). In iodine sufficient regions, PTCs are by far the most common subtype, while follicular cancers have been reported as relatively more common in iodine deficient regions. Because differentiated cancers are generally slow-growing and have a good prognosis, treatment of differentiated thyroid cancer has become more conservative with observation being a reasonable option for small (<1 cm) low-risk PTCs in patients with reliable follow-up, and less extensive surgery and less frequent use of radioactive iodine employed for low risk differentiated cancers.

Many thyroid nodules and cancers are diagnosed incidentally by ultrasound (U/S) and other imaging modalities. However, radiological screening for thyroid nodules and cancers is not recommended. Because the majority of thyroid nodules are not life threatening and hence do not require surgery, investigation of a thyroid nodule is
directed at identifying the minority of cases that require thyroid surgery, as opposed to observation or simple reassurance. The principal diagnostic tools used for thyroid nodules and cancers and to avoid unnecessary surgery are thyroid U/S and fine needle aspiration cytology (FNAC).14

International guidelines for management of thyroid nodules and cancers such as those of the American Thyroid Association (ATA) and National Comprehensive Cancer Network (NCCN) assume the availability of thyroid stimulating hormone (TSH) assays, U/S, FNAC, thyroid scans, radioactive iodine (RAI), thyroid and calcium monitoring and replacement, and reliable follow-up.15,16 However, in low resource settings, such as those found in developing countries, these studies and interventions frequently are not available or are unaffordable.7,17 Compliance and/or scheduling of follow-up examinations may also be unreliable. Hence, international guidelines for management of thyroid nodules and cancers often cannot be applied to low resource settings.

Without resource-appropriate guidelines for thyroid nodules and cancers, domestic surgeons (and even volunteer surgeons visiting from higher-resource settings) have little guidance with regard to best practice when working in limited-resource settings. Failure to take resource limitations into account may lead to inappropriate surgery, over-investigation or, in the worst-case scenario, even have life-altering or fatal consequences associated with unforeseen perioperative complications or postoperative sequelae. Herein are presented diagnostic and treatment guidelines for management of thyroid nodules and thyroid cancer in low resource settings.

2 | METHODS

The African Head and Neck Society (AfHNS) convened a task force of thyroid specialists to review thyroid nodule and thyroid cancer management guidelines for low resource settings, with a particular focus on preoperative, perioperative, and postoperative decision making. This international collaboration included otolaryngologists and general surgeons with expertise in head and neck endocrine surgery from across the globe, including members of the AfHNS and American Head & Neck Society (AHNS) Endocrine Section. The task force met in Cape Town in December 2018.

A comprehensive literature review using the PubMed and Cochrane libraries was performed. The search strategy used the following algorithm: (“thyroid cancer” or “thyroid neoplasm” or “thyroid nodule” or “thyroid carcinoma”) and (“evaluation” OR “diagnosis” or “imaging” or “management” or “treatment” or “neck dissection” or “surgery”) and (“developing” or “resource poor” or “low resource” or “underdeveloped” or “less developed” or “emerging” or “third world”) and (“Countries” or “Nations” or “Area” or “Region”).

The information gathered in this literature review guided the development of task force recommendations—with supplementation by expert opinion and society guidelines when information regarding a particular subject was lacking. In particular, the 2018 NCCN Clinical Practice Guidelines for thyroid carcinoma were used as a framework and adapted for limited resource settings. Low resource scenarios were created by systematically removing elements, such as availability of TSH, U/S, RAI, and so on, from the NCCN diagnostic and management criteria. The task team used the ADAPTE process, a validated systematic approach to amending evidence-based clinical practice guidelines (Figure 1), to modify diagnostic and treatment protocols developed for resource-rich environments to account for the constraints of low resource settings.18 Each recommendation that was developed was categorized based on the level of evidence and consensus, similar to system utilized by the NCCN16.

Category 1: high level evidence and uniform consensus of the authors.

FIGURE 1 Summary of the ADAPTE process used to create low resource guidelines for thyroid nodule and cancer management [Color figure can be viewed at wileyonlinelibrary.com]
Category 2A: lower-level evidence with uniform consensus of the authors.

Category 2B: lower-level evidence with consensus (not uniform) of the authors.

Category 3: any level of evidence where there is significant disagreement between the authors.

It should be noted that there are many reasons why a particular resource could be considered “unavailable,” including a lack of technology or equipment, delays in availability of resources, and/or poor quality of available resources. In this study, we consider low-resource environments as any setting where particular resources are either physically unavailable, financially unavailable, or practically unavailable if the quality of the test is poor on account of inadequate equipment (e.g., ultrasound or FNA equipment) or expertise (e.g., radiologist/surgeon experienced with thyroid ultrasound or pathologist capable of interpreting thyroid cytopathology). Therefore, a low resource setting can refer to a rural or less developed region within a more developed country, or to a particular patient for whom resources are inaccessible even within an otherwise resource-rich region.

3 | RECOMMENDATIONS

3.1 | Evaluation of thyroid nodule or mass in low resource settings

Nodularity of the thyroid gland is common in the general population, and the majority of thyroid nodules are benign and do not require surgical excision.³¹⁹ Nodules may be detected on incidental neck palpation or by U/S imaging, with the important caveat that standardized screening for healthy adults is not recommended by the U.S. Preventative Services Task Force.¹³ Thyroid cancer is estimated to be present in approximately 5% of thyroid nodules,³²⁰ although this rate may be higher in low resource settings.⁴

To rule out thyroid cancer, the standard diagnostic workup consists of a thyroid U/S with FNAC.¹⁵,¹⁶ Ultrasound is universally agreed to be the most sensitive and specific initial imaging modality for thyroid nodules, and while U/S is generally available in most settings, the quality of the U/S varies substantially with the experience of the ultrasonographer. Additionally, in high-resource settings, indeterminate thyroid nodules can be evaluated with molecular genetics to aid in risk stratification,¹⁵ but this resource-intensive and expensive technology is almost never available in low resource settings.

Serum TSH is standardly checked to evaluate thyroid function at the time of thyroid nodule evaluation. When TSH is not available, clinical signs and symptoms may be used to determine the probability of a hyperthyroid or euthyroid/hypothyroid state. A clinically validated method is Wayne’s Index, with reported positive predictive value of 95% and negative predictive value of 90%²¹,²² (Table 1). In situations of hyperthyroidism, a radioactive iodine uptake test may be employed to evaluate the functionality of a thyroid nodule.²³ As any combination of these studies may not be available in low resource settings (Figure 2), clinicians must often rely on alternative clinical evaluation and diagnostic criteria.

**Recommendation 1**: When U/S is unavailable, the history and physical examination of the thyroid and neck may yield features suggestive of higher risk of malignancy, such as rapid growth, firm mass, thyroid asymmetry, cervical lymphadenopathy, recent onset of hoarseness, and vocal cord paralysis. When U/S is unavailable, these high-risk clinical features are indications for FNAC.

Level of evidence: 2A.

**Recommendation 2**: CT or MRI should be considered to assess a thyroid nodule only when U/S is not available. These imaging modalities have poorer sensitivity and specificity and are more expensive than U/S.

Level of evidence: 1.

**Recommendation 3**: Clinical signs and symptoms may be used to determine the probability of a hyperthyroid or euthyroid/hypothyroid state when TSH testing is not available. Wayne’s Index can be used as a clinically validated assessment score.

Level of evidence: 2A.

**Recommendation 4**: Other than a rapidly growing thyroid mass, biopsy of a thyroid nodule is typically not urgent, and referral to a better-resourced center for FNAC is recommended if possible.

Level of evidence: 1.

**Recommendation 5**: If referral for FNAC is not possible, clinical and U/S findings may be employed to risk-stratify thyroid nodules using the Thyroid Imaging Reporting and Data System (TI-RADS) (http://tiradscalculator.com/). Patients with high-risk clinical and sonographic features are advised to have surgery with histopathologic review of the thyroid specimen.

Level of evidence: 1.

3.2 | Surgical options for thyroid tumors in low-resource settings

Surgical intervention may be indicated for thyroid nodules or cancer in low resource settings for either diagnostic evaluation or definitive management. While FNAC is the preferred diagnostic methodology, a diagnostic lobectomy (or nodulectomy in select cases) may be performed
to determine tumor histopathology when FNAC is unavailable. Complete thyroid lobectomy is preferred over thyroid nodulectomy in cases where adequate thyroid hormone is available, unless the nodule is located in the isthmus, wherein a thyroid isthmusectomy may be performed.

However, situations in which patients do not have access to thyroid hormone monitoring and replacement require careful consideration. On the one hand, approximately 25% of thyroid lobectomy patients ultimately develop hypothyroidism\(^{24,25}\) with resultant quality of life implications in patients who are not adequately supplemented with thyroid hormone. On the other hand, all other things considered, it is generally safest to perform a complete thyroid lobectomy with identification of the recurrent laryngeal nerve (RLN), rather than a thyroid nodulectomy, where the RLN may not be identified and therefore could be at increased risk for injury. Additionally, when considering a thyroid nodulectomy, the location of the nodule within the thyroid gland is an important factor, with superficially located anterior, superior, and inferior thyroid nodules posing much less risk of nerve injury with excision than posterior nodules. In a low-resource setting without access to thyroid hormone, a surgeon must carefully weigh the risk of lifelong hypothyroidism with the risk of RLN injury, considering the size and location of the thyroid nodule.

For diagnosed thyroid carcinoma, surgical resection is generally recommended as a primary form of treatment in the vast majority of cases.\(^{16}\) However, in a low-

### Table 1: Clinical assessment scores for Wayne’s Index

| Symptoms                        | Score | Signs               | Present | Absent |
|---------------------------------|-------|---------------------|---------|--------|
| Preference for cold             | 5     | Hyperkinesis        | 4       | -2     |
| Excessive sweating              | 3     | Atrial fibrillation | 4       | 0      |
| Appetite increased              | 3     | Palpable thyroid    | 3       | -3     |
| Weight decreased                | 3     | Pulse >90 beats/min | 3       | 0      |
| Palpitations                    | 2     | Bruit over thyroid  | 2       | -2     |
| Tiredness                       | 2     | Exophthalmos        | 2       | 0      |
| Nervousness                     | 2     | Lid retraction      | 2       | 0      |
| Dyspnea on effort               | 1     | Hands hot           | 2       | -2     |
| Appetite decreased              | -3    | Lid lag             | 1       | 0      |
| Weight increased                | -3    | Hands moist         | 1       | -1     |
| Preference for heat             | -5    | Pulse >80 beats/min | 0       | -3     |

Note: Score of >19 indicates hyperthyroidism; score of <11 indicates euthyroid state.
resource setting, the degree of thyroid resection should be carefully considered in light of how the extent of thyroid surgery may influence perioperative complications and long-term quality of life. Total thyroidectomy is not recommended in settings without adequate thyroid hormone and/or calcium monitoring and replacement. As approximately 25% of thyroid lobectomies patients have been found to develop hypothyroidism, even thyroid lobectomies must be carefully evaluated in low resource settings. Similarly, hypoparathyroidism can be a fatal perioperative complication and remains a possible contraindication to total thyroidectomies when adequate supplementation is unavailable.

In environments where total thyroidectomy cannot be safely performed due to aforementioned resource constraints, a thyroid lobectomy or subtotal thyroidectomy may be considered. The Dunhill procedure is a type of subtotal thyroidectomy procedure that involves complete removal of one thyroid lobe with preservation of the superior and posterior thyroid on the contralateral side. With this procedure, the posterior thyroid tissue near the cricothyroid joint is preserved, with the intent of not disturbing the RLN, although failure to identify the nerve does potentially pose increased risk of injury. Similarly, the intent of preservation of the superior and posterior thyroid tissue is to increase the likelihood of preservation of the superior parathyroid glands, which are generally located along the posterosuperior aspect of the gland. Risks of subtotal thyroidectomy include hemorrhage, RLN injury, tumor recurrence, and the understanding that any future revision surgery will be more challenging in a setting of incomplete thyroid removal.

Recommendation 6: Surgeries less than total thyroidectomy should be performed when a patient does not have reliable access to postoperative thyroid or calcium monitoring and replacement.

Level of evidence: 2A

Recommendation 7: If FNAC is not available, an open surgical excisional biopsy may be performed in patients with high-risk clinical and sonographic features. For patients with access to thyroid hormone monitoring and replacement, diagnostic complete thyroid lobectomy should be performed rather than nodulectomy.

Level of evidence: 2A

Recommendation 8: For patients without access to thyroid hormone monitoring and replacement, a thyroid nodulectomy may be considered in the diagnostic evaluation and management of thyroid nodules. Nodules in the thyroid isthmus or positioned anteriorly within the thyroid are most favorable for diagnostic nodulectomy, as risk to the RLN and parathyroid glands are lower for nodules in these locations. It must be recognized that while nodulectomy may decrease incidence of postoperative hypothyroidism as compared to thyroid lobectomy, risk of injury to the RLN may be increased depending on the location of the nodule within the thyroid, the trajectory of the RLN, and the experience of the surgeon. Nodulectomy for posteriorly located thyroid nodules should be avoided due to higher risk of RLN injury.

Level of evidence: 2B.

Recommendation 9: Subtotal thyroidectomy (eg, Dunhill procedure) is a surgical option for patients with benign thyroid goiters and thyroid cancers who require bilateral thyroid surgery but who cannot undergo total thyroidectomy due to lack of access to thyroid or calcium monitoring and replacement.

Level of evidence: 2A.

### 3.3 | Management of papillary thyroid cancer in low-resource settings

PTC accounts for approximately 85% of all thyroid carcinomas, although this rate is lower in iodine deficient regions due to a higher incidence of FTC. PTC is a well-differentiated thyroid cancer that is generally associated with slow tumor growth and good prognosis and outcomes. Most cases of PTC occur sporadically, but some known risk factors include radiation exposure to the neck and genetic syndromes including familial adenomatous polyposis and Cowden syndrome.

Initial management of PTC is often stratified based on tumor size. Large tumors (>4 cm) generally are recommended for total thyroidectomy with possible central neck dissection, whereas small tumors (<4 cm) may be treated by either a lobectomy or total thyroidectomy. High-risk tumor features include large tumor size (>4 cm), significant gross extrathyroidal or extranodal extension, bulky cervical lymph node metastases, and distant metastases. Postoperative RAI presupposes that the thyroid gland has been removed, and therefore these high-risk features often become indications for upfront total thyroidectomy. However, in low resource settings wherein RAI is not available, the decision for total thyroidectomy should not be based upon indications for postoperative RAI.

In appropriately resourced settings, elective central neck dissection is generally only recommended for larger (> 4 cm) papillary thyroid cancers, and often it is not recommended electively in any circumstance. In low-resource settings, especially in environments where calcium monitoring and replacement are not readily available, all four parathyroid glands cannot be put at risk, as the risk of harm from life-threatening hypoparathyroidism and hypocalcemia outweigh any potential benefit.
Therefore, when calcium monitoring and replacement are not available, unilateral papillary thyroid cancer can safely be treated with unilateral surgery (thyroid ± central lymph node dissection in appropriate cases), whereas modifications to the surgical plan must be made for cases with bilateral disease such that all four parathyroid glands are not put at significant risk (typically precluding total thyroidectomy and/or bilateral central compartment dissection). Additionally, since gross intraoperative assessment of lymph nodes generally has poor correlation with final pathology, surgeons in low resource environments should especially exercise caution in putting all four parathyroid glands at risk in any situation based on presence of intraoperatively identified lymph nodes.

**Recommendation 10:** In situations when thyroid and calcium replacement are unavailable, management of PTC may be stratified based on the extent of disease. For a tumor less than 2 cm in size with no gross extrathyroidal extension in a patient less than 55 years old, observation with follow-up U/S may be most appropriate. For thyroid cancers larger than 2 cm that do not extend to the contralateral lobe, the recommended surgery is either a lobectomy or nodulectomy. In cases where more extensive disease is present bilaterally, a subtotal thyroidectomy may be performed if the disease can be completely excised while still preserving sufficient thyroid remnant and avoiding putting all four parathyroid glands at risk. A unilateral central neck dissection may be performed in patients with clinically apparent or FNA proven lymph node metastases (Figure 3).

Level of evidence: 2A.

**Recommendation 11:** In an environment wherein RAI is unavailable, a thyroid lobectomy is recommended for unilateral PTC, regardless of tumor size, extrathyroidal or extranodal extension, or distant metastasis. In patients with bilateral thyroid disease and/or bilateral cervical lymph node involvement, total thyroidectomy with or without central neck dissection may be indicated. In instances of lateral neck lymphadenopathy, a respective lateral neck dissection (levels II-Vb) should also be performed (Figure 4).

Level of evidence: 2A.

### 3.4 | Management of follicular and Hürthle cell carcinomas in low-resource settings

FTC represents approximately 10% of thyroid carcinoma, and HTC makes up <2% of thyroid cancers. Lymphatic involvement is rarely observed for FTC whereas HTC has a propensity for both vascular and lymphatic spread. The Bethesda System is commonly used to report thyroid cytology and direct treatment options. Bethesda Stage III corresponds to a follicular lesion or atypical cells of undetermined significance, while Bethesda IV indicates

---

**AfHNS thyroid management guidelines: papillary/suspicious for papillary carcinoma**

| FNAC result | Diagnostic procedure | Pre/intraoperative decision-making criteria | Primary treatment |
|-------------|----------------------|------------------------------------------|-------------------|
| Normal      | U/S thyroid and neck | <2cm tumour Young patient (<55yrs) No gross extrathyroidal extension | Observation with follow-up ultrasound |
|             | CT/MRI for fixed/bulky/subternal tumour | Disease does not extend to contralateral lobe | Lobectomy +/- isthmusectomy |
|             | FNAC of suspicious lateral neck nodes | Disease extends to contralateral lobe Goals of surgery: Completely excise disease Avoid hypothyroidism and hypoparathyroidism/hypocalcemia | Nodulectomy* |
|             | Vocal cord mobility | | |

*While thyroid lobectomy would almost always be preferred over nodulectomy in situations with adequate thyroid hormone monitoring and replacement, in low-resource settings where thyroid hormone monitoring and replacement is not available, nodulectomy may be considered in cases where nodules are located superficially and anteriorly in the thyroid lobe. It must be recognized that while nodulectomy may decrease incidence of postoperative hypothyroidism as compared to thyroid lobectomy, risk of injury to the recurrent laryngeal nerve may be increased depending on the location of the nodule within the thyroid, the trajectory of the recurrent laryngeal nerve, and the experience of the surgeon.

**FIGURE 3** Management algorithm for PTC in setting without calcium or thyroid hormone replacement [Color figure can be viewed at wileyonlinelibrary.com]
cytopathology identified as a follicular neoplasm or Hürthle cell lesion/neoplasm. However, cytopathology from FNAC cannot be used reliably to distinguish between benign and malignant follicular growths, since the diagnosis requires histopathologic evidence of vascular or capsular invasion. Thus, Bethesda Stage III and IV classified FNAC specimens have only an approximate 15% and 25% risk of ultimately representing a thyroid carcinoma.

While the Bethesda system is commonly employed to risk stratify nodules in resource-rich environments, cytopathology is often not available in low resource environments. In these situations, if U/S is available, the TI-RADS classification can be employed to risk stratify nodules based on ultrasonographic features. If neither cytopathology or U/S are available, then the clinician must use clinical exam findings such as growth, firmness, presence of associated lymphadenopathy, and vocal cord paralysis/voice changes in order to risk stratify patients with thyroid nodules/masses.

**Recommendation 12:** In a low-resource setting without thyroid hormone and/or calcium monitoring and replacement, indeterminate (Bethesda III and IV) thyroid lesions/neoplasms should generally be observed, unless the lesion demonstrates highly suspicious ultrasonographic features or demonstrates growth over time. With growth or suspicious ultrasonographic features, thyroid lobectomy (or nodulectomy in select cases) may be considered. The decision for diagnostic thyroid lobectomy for larger or posteriorly located Bethesda III and IV nodules should be counterbalanced with the understanding that patients with chronically low thyroid hormone (without access to thyroid hormone replacement and monitoring) may have decreased quality of life.

**Level of evidence:** 2A

**Recommendation 13:** In a low-resource setting without thyroid hormone and/or calcium monitoring and replacement, if a diagnostic lobectomy (or nodulectomy in select cases) indicates minimally invasive follicular carcinoma or follicular carcinoma with vascular invasion, or if surgical pathology is unavailable, completion thyroideectomy is not recommended (Figure 5).

**Level of evidence:** 2A

**Recommendation 14:** In a low-resource setting without thyroid hormone and/or calcium monitoring and replacement, subtotal thyroidectomy should only be considered for follicular lesions/neoplasms if there is bilateral disease, and if the disease can be completely excised while still preserving sufficient thyroid remnant and avoiding putting all four parathyroid glands at risk (Figure 5).

**Level of evidence:** 2A

**Recommendation 15:** In the event that postoperative RAI is not available when considering surgery for a neoplasm suspicious for FTC or HTC, total thyroidectomy should be performed only in cases of bilateral tumor extension or bilateral cervical lymph node metastases.

**Level of evidence:** 2A.

## 3.5 Management of medullary thyroid cancer in low-resource settings

Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor of the parafollicular (C) cells of the thyroid gland, representing about 2% of thyroid carcinoma cases. The majority of MTC occur sporadically, but...
approximately 25% of cases are hereditary, associated with a RET proto-oncogene mutation and multiple endocrine neoplasia type 2 (MEN2) syndrome. Total thyroidectomy and central compartment dissection are recommended for MTC management by the NCCN and ATA guidelines, but this is predicated on availability of calcium and thyroid hormone monitoring and replacement after surgery. Elective lateral neck dissection has been variably advocated based on serum calcitonin levels, although recent investigation suggests that observation of the lateral neck in the absence of ultrasonographically apparent neck disease results in similar biochemical cure and ultimate locoregional control.

**Recommendation 16:** When thyroid and calcium monitoring and replacement are not available, a total thyroidectomy cannot be performed for MTC. In these situations, a lobectomy may be considered for unilateral MTC thyroid disease, with consideration for an ipsilateral central neck dissection. For bilateral MTC thyroid disease, subtotal thyroidectomy may be considered, if the disease can be completely excised while still preserving sufficient thyroid remnant and avoiding putting all four parathyroid glands at risk. Depending upon the burden of bilateral disease, the risks of hypothyroidism and hypocalcemia must be balanced with desire for complete tumor removal.

Level of evidence: 2A.

**Recommendation 17:** In the absence of radiographically apparent disease in the lateral neck, elective lateral neck dissection for MTC is generally not recommended. For patients who do not have access to ultrasound and/or cross-sectional imaging of the lateral neck, elective lateral neck may be considered, especially in cases wherein there is gross disease in the ipsilateral central neck.

Level of evidence: 2A.

**4 | CONCLUSIONS**

Successful management of thyroid neoplasms in low-resource settings often requires adaptation of existing treatment paradigms. Standard evaluation of thyroid nodules is predicated on the availability of U/S, serum TSH, thyroid scans, and/or FNAC. Clinical findings and assessment scores such as Wayne’s Index provide an alternative method for evaluating thyroid function in the absence of serum TSH. Similarly, clinical identification of the features of malignant thyroid masses such as rapid growth,
firm mass, thyroid asymmetry, cervical lymphadenopathy, recent onset of hoarseness, and vocal cord paralysis takes on greater significance in the absence of conventional diagnostic imaging and FNAC.

While definitive surgical resection is the standard of care for thyroid neoplasms and cancers, extent of thyroid surgery should be carefully considered in low-resource settings, especially among populations without access to calcium and thyroid hormone replacement or radioactive iodine. For patients with thyroid cancer, appropriate surgery must be tailored based on a number of factors including histopathology, disease extension, and resource availability, as perioperative complications such as hypocalcemia and/or hypothyroidism may be worse than not treating the disease at all. Referral to higher-resource environments is occasionally an option and highly encouraged when possible, but more often than not patients in low-resource environments simply do not have access to higher levels of care.

Detailed discussion of cost of specific technologies, medications, and procedures in various low resource settings, as well as general solutions for lack of health care resources globally, are largely beyond the scope of these guidelines. However, the advent of portable U/S in particular represents a unique opportunity to introduce relatively low-cost technology for the basic evaluation of thyroid masses. Telecytopathology represents another example of how the integration of technology and education may contribute to bridging resource gaps in the evaluation and treatment of thyroid nodules and cancers. The integration of new lower cost technologies into low resource health care environments should ideally be accompanied by educational collaborations between developed and developing countries.

The complete set of AfHNS thyroid nodule and cancer treatment algorithms can be found at the following link: https://developingworldheadandneckcancerguidelines.com/. Overall, these conjoint AfHNS and AHNS Endocrine Section guidelines provide a systematic methodology of evaluating and treating thyroid nodules and cancers while operating within the constraints of limited resource environments.

REFERENCES

1. Reiners C, Wegscheider K, Schicha H, et al. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid. 2004;14(11):926-932. https://doi.org/10.1089/thy.2004.14.926.

2. Frates MC, Benson CB, Doublet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006;91(9):3411-3417. https://doi.org/10.1210/jc.2006-0690.

3. Werk EE, Vernon BM, Gonzalez JJ, Ungaro PC, McCoy RC. Cancer in thyroid nodules: a community hospital survey. Arch Intern Med. 1984;144(3):474-476. http://www.ncbi.nlm.nih.gov/pubmed/6703815.

4. Bhuiyan MMZU, Machowski A. Nodular thyroid disease and thyroid malignancy: experience at Polokwane Mankweng Hospital Complex, Limpopo Province, South Africa. S Afr Med J. 2015;105(7):570-572. https://doi.org/10.7196/SAMJnew.7885.

5. Sisson JC. Medical treatment of benign and malignant thyroid tumors. Endocrinol Metab Clin North Am. 1989;18(2):359-387.

6. Mulauzdi TV, Ramdial PK, Madiba TE, Callaghan RA. Thyroid carcinoma at King Edward VIII Hospital, Durban, South Africa. East Afr Med J. 2001;78(5):242-245. https://doi.org/10.4314/eamj.v78i5.9046.

7. Maniakas A, Davies L, Zafereo ME. Thyroid disease around the world. Otolaryngol Clin North Am. 2018;51(3):631-642. https://doi.org/10.1016/j.otc.2018.01.014.

8. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. J Clin Oncol. 2016;38(10):2783-2795. https://doi.org/10.1200/JCO.2015.67.36(16)30172-6.

9. Tam S, Boonsripitayanon M, Amit M, et al. Survival in differentiated thyroid cancer: comparing the AJCC cancer staging seventh and eighth editions. Thyroid. 2018;28(10):1301-1310. https://doi.org/10.1089/thy.2017.0572.

10. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol. 2018;44(3):307-315. https://doi.org/10.1016/j.ejso.2017.03.004.

11. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20(11):1235-1245. https://doi.org/10.1089/thy.2009.0455.

12. lamartina L, Durante C, Fletti S, Cooper DS. Low-risk differentiated thyroid cancer and radiiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab. 2015;100(5):1748-1761. https://doi.org/10.1210/jc.2014-3882.

13. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. JAMA. 2017;317(18):1882-1887. https://doi.org/10.1001/jama.2017.4011.

14. Haugen BR. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017;123(3):372-381. https://doi.org/10.1002/cncr.30360.

15. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the
American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133. https://doi.org/10.1089/thy.2015.0020.

16. About the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). https://www.nccn.org/professionals/. Accessed February 25, 2019.

17. Sakafu LL, Mselle TF, Mwaiselage JD, Maunda KK, Eddin BS, Zafereo ME. Thyroid cancer and iodine deficiency status: a 10-year review at a single cancer Center in Tanzania. OTO Open. 2018;2(2):2473974X18777238. https://doi.org/10.1177/2473974X18777238.

18. Fervers B, Burgers JS, Voellinger R, et al. Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf. 2011;20(3):228-236. https://doi.org/10.1136/bmjqs.2010.043257.

19. Belfiore A, Giuffrida D, La Rosa GL, et al. High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinol. 1989;121(2):197-202.

20. Lin J-D, Chao T-C, Huang B-Y, Chen S-T, Chang H-Y, Hsueh C. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid. 2005;15(7):708-717. https://doi.org/10.1089/thy.2005.15.708.

21. Naraintrnan S, David SK, Raveendran K, Pillai B. Accuracy of Wayne’s criteria in diagnosing hyperthyroidism: a prospective study in South Kerala, India. Int Surg J. 2018;5(4):1267. https://doi.org/10.18203/2349-2902.isj20181056.

22. Crooks J, Murray IP, Wayne EJ. Statistical methods applied to the clinical diagnosis of thyrotoxicosis. Q J Med. 1959;28(110):211-234.

23. Bomeli SR, LeBeau SO, Ferris RL. Evaluation of a thyroid nodule. Otolaryngol Clin North Am. 2010;43(2):229-238, vii. https://doi.org/10.1016/j.octc.2010.01.002.

24. Said M, Chiu V, Haigh PI. Hypothyroidism after hemi-thyroidectomy. World J Surg. 2013;37(12):2839-2844. https://doi.org/10.1007/s00268-013-2201-8.

25. Dedivitis RA, Aires FT, Cernea CR. Hypoparathyroidism after thyroidectomy: prevention, assessment and management. Curr Opin Otolaryngol Head Neck Surg. 2017;25(2):142-146. https://doi.org/10.1097/MO.0000000000000346.

26. Kurmann A, Herden U, Schmid SW, Candinas D, Seiler CA. Morbidity rate of reoperation in thyroid surgery: a different point of view. Swiss Med Wkly. 2012;142:w13643. https://doi.org/10.4444/smww.2012.13643.

27. Mazzaferrri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-428.

28. Schneider AB, Sarne DH. Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nat Clin Pract Endocrinol Metab. 2005;1(2):82-91. https://doi.org/10.1038/ncpemet0022.

29. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223-262. https://doi.org/10.1038/ajg.2014.435.

30. Gonçalves Filho J, Zafereo ME, Ahmad FI, et al. Decision making for the central compartment in differentiated thyroid cancer. Eur J Surg Oncol. 2018;44(11):1671-1678. https://doi.org/10.1016/j.ejso.2018.08.005.

31. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338-1348. https://doi.org/10.1001/jama.2017.2719.

32. Grebe SK, Hay JD. Follicular thyroid cancer. Endocrinol Metab Clin North Am. 1995;24(4):761-801.

33. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341-1346. https://doi.org/10.1089/thy.2017.0500.

34. Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid. 2001;11(7):637-645. https://doi.org/10.1089/108072501750362709.

35. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009;19(11):1159-1165. https://doi.org/10.1089/thy.2009.0274.

36. Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14(5):587-595. https://doi.org/10.1016/j.jacr.2017.01.046.

37. Wells SA, Asa SL, Drale H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. https://doi.org/10.1089/thy.2014.0335.

38. Drale H, Machens A. Surgical management of the lateral neck compartment for metastatic thyroid cancer. Curr Opin Oncol. 2013;25(1):20-26. https://doi.org/10.1097/CCO.0b013e328359ff1f.

39. Pena I, Clayman GL, Grubbs EG, et al. Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head Neck. 2018;40(1):79-85. https://doi.org/10.1002/hed.24969.

40. Becker DM, Tafoya CA, Becker SL, Kruger GH, Tafoya MJ, Becker TK. The use of portable ultrasound devices in low- and middle-income countries: a systematic review of the literature. Trop Med Int Health. 2016;21(3):294-311. https://doi.org/10.1111/tmi.12657.

41. Costa C, Pastorello RG, Mendonça A, et al. Use of a low-cost telecytopathology method for remote assessment of thyroid FNAs. Cancer Cytopathol. 2018;126(9):767-772. https://doi.org/10.1002/cncy.22026.

42. Fagan JJ, Zafereo M, Aswani J, Netterville JL, Koch W. Head and neck surgical subspecialty training in Africa: sustainable models to improve cancer care in developing countries. Head Neck. 2017;39(3):605-611. https://doi.org/10.1002/hed.24591.

43. Fagan JJ, Aswani J, Otiti J, et al. Educational workshops with graduates of the University of Cape Town Karl Storz Head and neck surgery fellowship program: a model for collaboration in outreach to developing countries. Springerplus. 2016;5(1):1652. https://doi.org/10.1186/s40064-016-3290-2.

How to cite this article: Zafereo M, Yu J, Onakoya PA, et al. African Head and Neck Society Clinical Practice guidelines for thyroid nodules and cancer in developing countries and limited resource settings. Head & Neck. 2020;42:1746–1756. https://doi.org/10.1002/hed.26094.